NCT00218465View on ClinicalTrials.gov

Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking

PHASE2CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Nicotine Dependence
Interventions
DRUG

GW468816

Pharmacotherapies for Relapse Prevention

DRUG

Placebo Comparator: Placebo

Trial Locations (2)

02478 9106

McLean Hospital, Brain Imaging Center, Belmont

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Mclean Hospital

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Massachusetts General Hospital

OTHER